. Hospices-civils-de-lyon, Institut National de Veille Sanitaire/ Institut National du Cancer/ Francim/ Institut National de la Santé et de la Recherche Médicale. « Projections de l'incidence et de la mortalité par cancer en France en, 2010.

L. Menasce, G. White, and C. Harrisson, Localization of the estrogen receptor locus (ESR) to chromosome 6q25. 1 by FISH and a simple post-FISH banding technique, Genomics, vol.17, pp.263-268, 1993.

E. Enmark, M. Pelto-huikko, and K. Grandien, Human estrogen receptor betagene structure, chromosomal localization and expression pattern, J Clin Endocrinol Metab, vol.82, pp.4258-65, 1997.
DOI : 10.1210/jc.82.12.4258

D. Crémoux and P. , Hormonothérapie des cancers du sein, Bulletin du cancer, vol.98, issue.11, pp.1311-1320, 2011.

S. Cowley, S. Hoare, and S. Mosselman, Estrogen receptors alpha and beta form heterodimers on DNA, J Biol Chem, vol.272, pp.19858-62, 1997.

E. Jensen and V. Jordan, The estrogen receptor: a model for molecular medicine, Clin Cancer Res, vol.9, pp.1980-1989, 2003.

K. Petterson, K. Grandien, and G. Kuiper, Mouse estrogen receptor beta forms estrogen response element-binding heterodimers with estrogen receptor alpha, Mol Endocrinol, vol.11, pp.1486-96, 1997.

A. Brzozowski, A. Pike, and Z. Dauter, Molecular basis of agonism and antagonism in the oestrogen receptor, Nature, vol.389, pp.753-761, 1997.

N. Mckenna, R. Lanz, O. Malley, and B. , Nuclear receptor coregulators : cellular and molecular biology, Endocr Rev, vol.20, pp.321-365, 1999.

J. Norris, L. Paige, and D. Christensen, Peptide antagonists of the human estrogen receptor, Science, vol.285, pp.744-750, 1999.

M. Misrahi, M. Atger, and L. Auriol, Complete amino acid sequence of the human progesterone receptor deduced from cloned cDNA, Biochem Biophys Res Commun, vol.13, issue.1432, pp.740-748, 1987.

M. Rousseau-merck, M. Misrahi, and H. Loosfelt, Localization of the human progesterone receptor gene to chromosome 11q22-q23, Hum Genet, vol.77, issue.3, pp.280-282, 1987.

G. Kuiper and J. Gustafsson, The novel estrogen receptor-beta subtype: potential role in the cell-and promoter-specific actions of estrogens anti-estrogens, FEBS Lett, vol.87, p.41090, 1997.

D. Crémoux, P. Dieras, V. Poupon, and M. , Le tamoxifène et les inhibiteurs d'aromatase dans le traitement des cancers du sein : aspects pharmacologiques et cliniques, Bulletin du cancer, vol.91, issue.12, pp.917-944, 2004.

M. Donnel, D. Connor, C. Wijavaratne, and A. , Definition of the molecular and cellular mechanisms underlying the time selective agonist/ antagonist activities of selective estrogen receptor modulators, Recent Prog Horm Res, vol.57, pp.295-316, 2002.

J. Hall, M. Donnell, and D. , The estrogen receptor beta-isoform (ERbeta) of the human estrogen receptor modulates ER alpha transcriptional activity and is a key regulator of the cellular response to estrogens and antiestrogens, Endocrinology, vol.140, pp.5566-78, 1999.

R. Clarke, F. Leonessa, and J. Welch, Cellular and molecular pharmacology of antiestrogen action and resistance, Pharmacol Rev, vol.53, pp.25-71, 2001.

S. Ali and R. Coombes, Endocrine-responsive breast cancer and strategies for combating resistance, Nature Rev Cancer, vol.2, pp.101-113, 2002.

V. Jordan, Selective estrogen receptor modulator: a personal perspective, Cancer Res, vol.61, pp.5683-5690, 2001.

S. Oesterreich, Q. Zhang, and T. Hopp, Tamoxifen-bound estrogen receptor (ER) strongly interacts with the nuclear matrix protein HET/ SAF-B, a novel inhibitor of ER-mediated transactivation, Mol Endocrinol, vol.14, pp.369-81, 2000.

C. Osborne, D. Boldt, and G. Clark, Effects of Tamoxifen on human breast cancer cell cycle kinetics: accumulation of cells in early G1 phase, Cancer Res, vol.43, pp.3583-3588, 1983.

E. Musgrove, A. Wakeling, and R. Sutherland, Points of action of estrogen antagonists and a calmodulin antagonist within the MCF-7 human breast cancer cell cycle, Cancer Res, vol.49, pp.2398-404, 1989.

R. Wintson, P. Kao, and D. Kiang, Regulation of insulin-like growth factors by antiestrogen, Breast Cancer Res Treat, vol.31, pp.107-122, 1994.

C. Knabbe, M. Lippman, and L. Wakefield, Evidence that transforming growth factor beta is a hormonally regulated negative growth factor in human breast cancer cells, Cell, vol.48, pp.417-445, 1987.

A. Butta, K. Machennan, and K. Flanders, Induction of transforming growth factor ?1 in human breast cancer in vivo following tamoxifen treatment, Cancer Res, vol.52, pp.4261-4265, 1992.

V. Jordan and S. Robinson, Species-specific pharmacology of antiestrogen role of metabolism, Fed Proc, vol.46, pp.1870-1874, 1987.

J. Macgregor and V. Jordan, Basic guide to the mechanisms of antiestrogen action, Pharmacol Rev, vol.50, pp.151-96, 1998.

R. Love and V. Koroltchouk, Tamoxifen therapy in breast cancer control worldwide, Bull World Health Organ, vol.71, pp.795-803, 1993.

C. Osborne, H. Zhao, and S. Fuqua, Selective estrogen receptor modulators: structure, function, and clinical use, J Clin Oncol, vol.18, pp.3172-86, 2000.

J. Diez, Skeletal effects of selective oestrogen receptor modulators (SERM)

N. Daly-schveitzer, Cancérologie clinique, 2008.

M. Espie, H. Hocini, and A. Hamy, Hormonothérapie adjuvante des cancers du sein, Cancer du sein. Actualités thérapeutiques, pp.87-108, 2007.

B. Fisher, J. Dignam, and J. Bryant, Five versus more than five years of tamoxifen for lymph node-negative breast cancer: updated findings from the national Surgical Adjuvant Breast and Bowel Project B-14 randomized trial, J Natl Cancer Inst, vol.93, pp.684-690, 2001.

C. Coombes, R. , M. D. Ph, D. Hall, and E. , A randomized trial of Exemestane after two or three years of Tamoxifen Therapy in Postmenopausal women with primary breast cancer, N Engl J Med, vol.350, pp.1081-92, 2004.

T. L. Delozier, hormonothérapie du cancer du sein: la fin du Tamoxifène?, Bull Cancer, vol.92, pp.142-150, 2005.

A. Howell, J. Robertson, and A. P. , Comparison of fulvestrant versus tamoxifen for the treatment of advanced breast cancer in postmenopausal women previously untreated with endocrine therapy: a multinational, double-blind, randomized trial, J Clin Oncol, vol.22, pp.1605-1613, 2004.

B. Cutuli, J. Petit, and J. Fricker, Accidents thromboemboliques chez les patientes ménopausées sous traitement adjuvant par tamoxifène. Fréquence, facteurs de risque et possibilités de prévention, Bull Cancer, vol.82, pp.51-57, 1995.

C. Meier and H. Jick, Tamoxifen and risk of idiopathic venous thromboembolism

B. Fisher, J. Dignam, and J. Bryant, Five versus more than five years of tamoxifen therapy for breast cancer patients with negative lymph nodes and estrogen receptor positive tumors, J Natl Cancer Inst, vol.88, issue.21, pp.1529-1542, 1996.

K. Pritchard, A. Paterson, and N. Paul, Increased thromboembolic complication with concurrent tamoxifen and chemotherapy in a randomized trial of adjuvant therapy for women with breast cancer. National Cancer Institute of Canada Clinical Trials Group Breast Cancer Site Group, J Clin Oncol, vol.14, issue.10, pp.2731-2738, 1996.

S. Bakour, J. Gupta, and K. Khan, Risk factors associated with endometrial polyps in abnormal uterine bleeding, Int J Gynaecol Obstet, vol.76, issue.2, pp.165-173, 2002.

B. Fisher, J. Costantino, and C. Redmond, Endometrial cancer in tamoxifentreated breast cancer patients: finding from the National Surgical Adjuvant Breast and Bowel Project (NASBP) B-14, J Natl Cancer Inst, vol.86, issue.7, pp.527-564, 1994.

E. Veyria, C. Alexandre, and C. Olieric, Eviter les effets indésirables par interactions médicamenteuses, Comprendre et décider. Prescrire, le guide 2012, 2011.

E. Simpson, M. Mahendroo, and G. Means, Aromatase cytochrome P450, the enzyme responsible for estrogen biosynthesis, Endocr Rev, vol.15, pp.342-355, 1994.

D. Salle and E. , Novel aromatase and 5-reductase inhibitors, J Steroid Biochem Mol Biol, vol.49, pp.289-294, 1994.

R. Cash, A. Brough, and M. Cohne, Aminoglutethimide as an inhibitor of adrenal steroidogenesis mechanisms of action and therapeutic trials, J Clin Endocrinol, vol.27, pp.1239-1248, 1967.

T. Evans, Clinical applications of new aromatase inhibitors, Critical Reviews in OncologyHematology, vol.16, pp.129-143, 1994.

T. Suzuki, Y. Miki, and Y. Nakamura, Sex steroid-producing enzymes in human breast cancer, Endocr Relat Cancer, vol.12, pp.701-720, 2005.

V. Njar and A. Brodie, Comprehensive pharmacology and clinical efficacy of aromatase inhibitors, Drugs, vol.58, pp.233-255, 1999.

M. Baum, A. Budzar, and J. Cuzick, Anastrozole alone or in combinaison with tamoxifen versus tamoxifen alone for ajuvant treatment of postmenopausal women with early-stage breast cancer: results of the ATAC (Arimidex Tamoxifen Alone or in Combination) trial efficacy and safety update analyses, Cancer, vol.98, pp.1802-1810, 2003.

A. Howell, J. Cuzick, and A. Baum, of the ATAC (Arimidex Tamoxifen Alone or in Combination) trial after completion of 5 years adjuvant treatment for breast cancer, Lancet, vol.365, pp.60-62, 2005.

B. Thurlimann, A. Keshaviah, and A. Coates, A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer, N Engl J Med, vol.353, pp.2747-2757, 2005.

F. Boccardo, A. Rubagotti, and M. Puntoni, Switching to anastrozole versus continued tamoxifen treatment of early breast cancer: preliminary results of the Italian tamoxifen anastrozole trial, J Clin Oncol, vol.23, pp.5138-5147, 2005.

R. Jakesz, W. Jonat, and M. Gnant, Switching of postmenopausal women with endocrine responsive early breast cancer to anastrozole after 2 years adjuvant tamoxifen: combined results of ABCSG trial 8 and ARNO 95 trial, Lancet, vol.366, pp.455-462, 2005.

M. Dridi and A. Astier, Place des inhibiteurs de l'aromatase dans le traitement du cancer du sein : aspects pharmacologiques et cliniques, J Pharm Clin, vol.26, pp.5-14, 2007.

J. Bonneterre, A. Budzar, and J. Nabholtz, Anastrozole is superior to tamoxifen as first-line therapy in hormone receptor positive advanced breast carcinoma, Cancer, vol.92, pp.2247-2258, 2001.

H. Mouridsen, M. Gershanovich, and Y. Sun, Phase III study of letrozole versus tamoxifen as first-line therapy of advanced breast cancer in postmenopausal women: analysis of survival and update of efficacy from the International Letrozole Breast Cancer Group, J Clin Oncol, vol.21, pp.2101-2109, 2003.

A. Coates, A. Keshaviah, and B. Thurlimann, Five years of letrozole compared with tamoxifen as initial adjuvant therapy for postmenopausal women with endocrine-responsive early breast cancer: update of study BIG1-98, J Clin Oncol, vol.25, pp.486-492, 2007.

M. Kaufmann, W. Jonat, and J. Hilfrich, Improved overall survival in postmenopausal women with early breast cancer after anastrozole initated after treatment with tamoxifen compared with continued tamoxifen: the ARNO 95 study, J Clin Oncol, vol.25, pp.2664-2670, 2005.

K. Crew, H. Grenlee, and J. Capodice, Prevalence of joint symptoms in post menopausal women taking aromatase inhibitors for early-stage breast cancer, J Clin Oncol, vol.25, pp.3877-83, 2007.

K. Crew, Effect of acupuncture on joint symptoms related to adjuvant aromatase inhibitor therapy in postmenopausal breast cancer patients, breast cancer symposium 29 th annual meeting, 2006.

C. Presant, C. Kelly, and L. Bosserman, Aromatase inhibitor (AI)-associated arthralgie (A) and bone pain (BP): frequency and characterization in clinical practice, ASCO Annual Meeting Proceedings PartI, p.6137, 2006.

N. Henry, J. Giles, and D. Ang, Prospective characterization of musculoskeletal symptoms in early breast cancer patients treated with aromatase inhibitors, Breast Cancer Res Treat, pp.10549-10556, 1007.

T. Ohsako, K. Inoue, and N. Nagamoto, Joint Symptoms : A Practical Problem of Anastrozole, Breast Cancer, vol.13, pp.284-292, 2006.

M. Laroche, S. Borg, and S. Lassoued, Joint pain with aromatase inhibitors: abnormal frequency of Sjogren's Syndrome, J Rheumatol, vol.34, pp.2259-63, 2007.

L. Morales, S. Pans, and K. Verschueren, A prospective sutdy comparing clinical rheumatological findings and tenosynovial and synovial changes on magnetic resonance imaging of breast cancer patients receiving adjuvant aromatase inhibitors or tamoxifene. In: abstract 3053 presented at 30 th annual meeting Breast Cancer Symposium, 2007.

L. Morales, S. Pans, and R. Paridaens, Debilating musculoskeletal pain and stiffness with letrozole and exemestane: associated tenosynovial changes on magnetic resonance imaging, Breast Cancer Res Treat, vol.104, pp.87-91, 2007.

S. Dent, T. Divalentin, and L. Vandermeer, Long term toxicities in women with early stage breast cancer treated with aromatase inhibitors: data from a tertiary care center, Breast Cancer Res Treat, vol.100, 2006.

A. Buzdar, A. Trialists, and . Group, Clinical features of joint symptoms observed in the 'Arimidex', Tamoxifen, Alone or in Combination (ATAC) trial, ASCO Annual Meeting Proceedings, p.551, 2006.

D. Felson and S. Cummings, Aromatase inhibitors and the syndrome of arthralgias with estrogen deprivation, Arthritis Rheum, vol.52, pp.2594-2602, 2005.

M. Dawson-basoa and A. Gintzler, Estrogen and progesterone activate spinal ?opiate receptor analgesic mechanisms, Pain, vol.64, pp.169-77, 1996.

Y. Smith, C. Stohler, and T. Nochols, Pronociceptive and nociceptive effects of estradiol though endogenous opiod neurotransmission in women, L Neurosci, vol.26, pp.5777-85, 2006.

R. Josse, Roles for estrogen in bone loss and arthralgia during aromatase inhibitor treatment, Current Opinion in Oncology, vol.19, pp.1-8, 2007.

I. Thompson, P. Bidgood, and A. Petroczi, An alternative methodology for the prediction of adherence to anti HIV treatment, AIDS Res Ther, vol.6, issue.1, p.9, 2009.

A. Moreau and P. Queneau, La decision thérapeutique personnalisée. Observance médicamenteuse, Rev Prat, vol.55, pp.899-902, 2005.

L. Gordis, Conceptual and methodologic problems in measuring patient compliance, Compliance in health care, 1979.

J. Donovan and D. Blake, Patient non-compliance: deviance or reasoned decisionmaking?, Soc Sci Med, vol.34, pp.507-520, 1992.
DOI : 10.1016/0277-9536(92)90206-6

A. Partridge, J. Avorn, and S. Philipp, Adherence to therapy with oral antineoplasic agents, J Natl Cancer Inst, vol.94, pp.652-61, 2002.

P. Price, Education, psychology and « compliance », Diabetes Metab Res Rev, vol.24, pp.101-106, 2008.
DOI : 10.1002/dmrr.851

B. Fisher, J. Costantino, and R. C. , A randomized clinical trial evaluating tamoxifen in the treatment of patients with node negative breast cancer who have estrogen-receptor positive tumors, N Engl J Med, vol.320, pp.479-84, 1989.

J. Urquhart, Role of patient compliance in clinical pharmacokinetics. A review of recent research, Clin Pharmacokinet, vol.27, pp.202-217, 1994.

V. Ziller, M. Kalder, and U. Albert, Adherence to adjuvant endocrine therapy in postmenopausal women with breast cancer, Ann Oncol, vol.20, issue.3, pp.431-467, 2009.

T. Barron, R. Connolly, and K. Bennett, Early discontinuation of tamoxifen: a lesson for oncologists, Cancer, vol.109, pp.832-841, 2007.

A. Partridge, A. Lafoutain, and E. Mayer, Adherence to initial adjuvant anastrozole therapy among women with early stage breast cancer, J Clin Oncol, vol.26, pp.556-62, 2008.

A. Veronesi, M. Pizzichetta, and M. Ferlante, Tamoxifen as adjuvant after surgery for breast cancer and tamoxifen or placebo as chemoprevention in healthy women: different compliance with treatment, Tumori, vol.84, pp.372-377, 1998.

A. Levine, J. Richardson, and G. Marks, Compliance with oral drug therapy in patients with hematologic malignancy, J Clin Oncol, vol.5, pp.1469-76, 1987.

T. Pullar, S. Kumar, and H. Tindall, Time to stop counting the tablets?, Clin Pharmacol Ther, vol.46, pp.163-171, 1989.

P. Rudd, R. Byyny, and Z. V. , The natural history of medication compliance in a drug trial: limitations of pill counts, Clin Pharmacol Ther, vol.46, pp.169-76, 1989.

D. Waterhouse, K. Calzone, and C. Mele, Adherence to oral tamoxifen: a comparison of patient self-report, pill counts, and microelectronic monitoring, J Clin Oncol, vol.11, pp.1189-97, 1993.

K. Ruddy, E. Mayer, and A. Partridge, Patient adherence and persistence with oral anticancer treatment, CA Cancer J Clin, vol.59, pp.56-66, 2009.

V. Murthy, G. Bharia, and R. Sarin, Tamoxifen non-compliance: does it matter?, Lancet Oncol, vol.3, p.654, 2002.

A. Partridge, P. Wang, and E. Winer, Non adherence to adjuvant tamoxifen therapy in women with primary breast cancer, J Clin Oncol, vol.21, pp.602-606, 2003.

E. Grunfeld, M. Hunter, and P. Sikka, Adherence beliefs among breast cancer patients taking tamoxifen, Patient Educ Couns, vol.59, pp.97-102, 2005.
DOI : 10.1016/j.pec.2004.10.005

L. Atkins and L. Fallowfield, Intentional and non-intentional non-adherence to medication among breast cancer patients, Eur J Cancer, vol.42, pp.2271-2276, 2006.

A. Thompson, J. Dewar, and T. Fakey, Association of poor adherence to prescribed tamoxifen with risk of death from breast cancer, Presented at the American Society of Clinical Oncology Breast Cancer Symposium, 2007.

J. Avorn, J. Monette, and A. Lacour, Persistence of use of lipid-lowering medications: a cross national study, JAMA, vol.279, pp.1458-62, 1998.

M. Becker, Sociobehavioral determinants of compliance, Compliance with therapeutic regimens

W. Kehoe and R. Katz, Health behaviors and pharmacotherapy, Ann Pharmacother, vol.32, pp.1076-86, 1998.
DOI : 10.1345/aph.17418

R. Haynes, A critical review of the " determinants " of patient compliance with therapeutic regimens, Compliance with therapeutic regimens, pp.26-39, 1976.

G. Apolone, . Corli, E. Caraceni, and . Negri, Pattern and quality of care of cancer pain management. Results from the Cancer Pain Outcome Research Study Group, BR J Cancer, vol.100, pp.1566-1574, 2009.

C. Owusu, D. Buist, and T. Field, Predictors of Tamoxifen discontinuation among older women with estrogen receptor-positive breast cancer, J Clin Oncol, vol.26, pp.549-555, 2008.

C. Lee, P. Nicholson, and R. Souhami, Patient compliance with oral chemotherapy as assessed by a novel electronic technique, J Clin Oncol, vol.10, issue.6, pp.1007-1013, 1992.

R. Balkrishnan, Predictors of medication adherence in the ederly, Clin Ther, vol.20, pp.764-71, 1998.

R. Love, L. Cameron, and B. Connell, Symptoms associated with tamoxifen treatment in postmenopausal women, Arch Intern Med, vol.151, pp.1842-1847, 1991.

L. Osterberg and T. Blaschke, Adherence to medication. The New Englanf Journal of, Medecine, vol.353, pp.487-497, 2005.

P. Heather and M. Donald, BSc Amit et al. Interventions to enhance patient adherence to medication prescriptions, JAMA, vol.288, issue.22, pp.2876-2879, 2002.

A. Moreau and P. Queneau, Décision thérapeutique personnalisée. Observance médicamenteuse, Revue du praticien, vol.55, pp.899-902, 2005.

J. Ankri, L. Disert, D. Henrard, and J. , Comportements individuels face aux medicaments: de l'observance thérapeutique, à l'expérience de la maladie, analyse de la literature, Santé Publique, vol.4, pp.427-441, 1995.

M. Monane, R. Bohn, and G. Jh, Compliance with antihypertensive therapy among ederly Medicaid enrollees: the role of age, gender and race, Am J Public Health, vol.86, pp.1805-1813, 1996.

J. Bailey, M. Lee, and G. Somes, Risk factors for antihypertensive medication refill failure by patients under Medicaid managed care, Clin Ther, vol.18, pp.1252-62, 1996.

I. L. Jl, observance: clé de voute de traitement au long cours. Revue du praticien Médecine Générale, pp.142-144, 2008.

P. Wang, R. Bohn, and E. Knight, Noncompliance with antihypertensive medications: the impact of depressive symptoms and psychosocial factors, J Gen Int Med, 2002.

A. Bandura, Self-efficacity: toward a unifying theory of behavioral change, Psychol Rev, vol.84, pp.191-215, 1977.

J. Rotter, Generalized expectancies for internal locus of control of reinforcement, Psychol Monogr, vol.80, issue.609, 1966.

P. Herschbach, K. Book, T. Brandl, and M. Keller, Psychological distress in cancer patients assessed with an expert rating scale, Br J Cancer, vol.99, pp.37-43, 2008.

B. Johansson, Y. Brandberg, and M. Hellbom, Health-related quality of life and distress in cancer patients: results from a large randomized study, Br J Cancer, vol.99, pp.1975-1983, 2008.

E. Costanzo, S. Lutgendorf, and M. Mattes, Adjusting to life after treatment: distress and quality of life following treatment for breast cancer, Br J Cancer, vol.97, pp.1625-1631, 2007.

P. Herschbach, M. Keller, L. Knight, and T. Brandl, Psychological problems of cancer patients: a cancer distress screening with a cancer specific questionnaire, Br J Cancer, vol.91, pp.504-511, 2004.

D. Robinson, C. Renshaw, and C. Okello, Suicide in cancer patients in south East England from 1996 to 2005: a population based study, Br J Cancer, vol.101, pp.198-201, 2009.

C. Burgess, V. Cornelius, S. Love, and J. Graham, Depression and anxiety in women with early breast cancer: five year observational cohort study, BMJ, vol.330, p.702, 2005.

D. Kissane, B. Grabsch, and A. Love, Psychiatric disorder in women with early stage and advanced breast cancer: a comparative analysis, Aust N Z J Psychiatry, vol.38, pp.320-326, 2004.

M. Massie, Prevalence of depression in patients with cancer, J Natl Cancer Inst Monogr, vol.32, pp.57-71, 2004.

O. Connor, M. Christensen, S. Jensen, and A. , How traumatic is breast cancer? Post-traumatic stress symptoms (PTSS) and risk factors for severe PTSS at 3 and 15 months after surgery in a nationwide cohort of Danish women treated for primary breast cancer, Br J Cancer, vol.104, pp.419-426, 2011.

B. Hulka, J. Cassel, and L. Kupper, Communication, compliance and concordance between physicians and patients with prescribed medications, Ann J Public Health, vol.66, pp.847-53, 1976.

M. Stewart, J. Brown, and H. Boon, Evidence on patient-doctor communication, Cancer Prev Control, vol.3, pp.25-30, 1999.

K. Rainbird, J. Perkins, S. Fisher, and R. , The needs of patients with advanced, incurable cancer, Br J Cancer, vol.101, pp.759-764, 2009.

R. Horwitz and S. Horwitz, Adherence to treatment and health outcomes, Arch Intern Med, vol.153, pp.1863-1871, 1993.

A. Lemasson, B. Gay, and G. Duroux, Comment le médecin perçoit-il sa prise en compte des préoccupations du patient ? Une étude qualitative en soins primaires en Aquitaine, Medecine, vol.2, issue.1, pp.38-42, 2006.

G. Bonadonna and P. Valagussa, Dose-response effect of adjuvant chemotherapy in breast cancer, N Engl J Med, vol.304, pp.10-15, 1981.

B. Blackwell, The drug defaulter, Clin Pharmacol Ther, vol.13, pp.841-849, 1972.

R. Greenberg, Overview of patient compliance with medication dosing: a literature review, Clin Ther, vol.6, pp.592-601, 1984.

J. Reginster, Adherence and persistence: impact on outcomes and health care resources, Bone, vol.38, issue.2 2, pp.18-21, 2006.

E. Lehane and G. Mccarthy, Medication non-adherence-exploring the conceptual mire, Int J Nurse Pract, vol.15, issue.1, pp.25-31, 2009.

J. Urquhart and . Noncompliance, The ultimate absorption barrier, Novel drug delivery and its therapeutic applications, pp.127-164, 1989.

D. Rotter, J. Hall, and R. Merisca, Effectiveness of Interventions to Improve Patient Compliance, Medical Care, vol.36, issue.8, pp.1138-61, 1998.
DOI : 10.1097/00005650-199808000-00004

L. Hong, N. Md, . Msc, and A. Gagliardi, Multidisciplinary Cancer Conferences: Exploring Obstacles and Facilitators to their implantation, Ann S Clin Oncol, vol.6, issue.2, 2010.

R. Smalley, Patient education: we have a better system now, RN, vol.60, issue.19, pp.22-24, 1997.

J. Zabora, K. Brintzenhofeszoc, and B. Curbow, The prevalence of psychological distress by cancer site, Psycho-Oncology, vol.15, issue.1, pp.19-28, 2001.
DOI : 10.1002/1099-1611(200101/02)10:1<19::AID-PON501>3.0.CO;2-6

J. Zabora, K. Brintzenhofeszoc, and P. Jacobsen, A New Psychosocial Screening Instrument for Use With Cancer Patients, Psychosomatics, vol.42, issue.3, pp.241-246, 2001.
DOI : 10.1176/appi.psy.42.3.241

J. Zabora, R. Smith-wilson, and J. Fetting, An Efficient Method for Psychosocial Screening of Cancer Patients, Psychosomatics, vol.31, issue.2, pp.192-196, 1990.
DOI : 10.1016/S0033-3182(90)72194-9

F. Fawzy, N. Fawzy, and N. Arndt, Critical Review of Psychosocial Interventions in Cancer Care, Archives of General Psychiatry, vol.52, issue.2, pp.100-113, 1995.
DOI : 10.1001/archpsyc.1995.03950140018003

R. Stoman, P. Brown, and E. Aldama, The use of relaxation for the promotion of comfort and pain relief in persons with advanced cancer, Contemporary Nurse, vol.3, pp.6-12, 1994.

P. Goodwin, M. Leszcz, and J. Koopmans, Randomized trial of group psychosocial support in metastatic breast cancer: the BEST study : Breast Expressive Supportive Therapy Study, Cancer treatment Reviews, vol.22, issue.6, 1996.

M. Leszcz and P. Goodwin, The Rationale and Foundations Of Group Psychotherapy for Women with Metastatic Breast Cancer, International Journal of Group Psychotherapy, vol.13, issue.2, pp.245-273, 1998.
DOI : 10.1016/0277-9536(91)90178-F

M. Richardson, J. Post-white, and E. Grimm, Coping, life attitudes, and immune responses to imagery and group support after breast cancer treatment, Alternative Therapies in Health and Medicine, vol.3, pp.62-70, 1997.

L. Carlson and B. Bultz, Benefits of psychosocial oncology care: improved quality of life and medical cost offset, Health and Quality of Life Outcomes, vol.1, issue.1, p.8, 2003.
DOI : 10.1186/1477-7525-1-8

P. Ades, F. Pashkow, and G. Fletcher, A controlled trial of cardiac rehabilitation in the home setting using electrocardiographic and voice transtelephonic monitoring, American Heart Journal, vol.139, issue.3, pp.543-548, 2000.
DOI : 10.1016/S0002-8703(00)90100-5

B. Bonan, M. Berhoune, F. Benizri, and S. Burnel, Prise en charge pharmaceutique des patients cancéreux. Rôle des pharmaciens hospitaliers et officinaux, 2008.

F. Moreddu, Le conseil associé à une demande spontanée. Tome 2, 2 ème édition, Pro-officina, 2007.

F. Moreddu, Le conseil associé à une ordonnance. Tome 1, 2 ème édition, 2007.

R. Osmer, M. Friede, and E. Liske, Efficacy and Safety of Isopropanolic Black Cohosh Extract for Climacteric Symptoms, Obstetrics & Gynecology, vol.105, issue.5, Part 1, pp.1074-83, 2005.
DOI : 10.1097/01.AOG.0000158865.98070.89

G. Elkins, Pilot evaluation of hypnosis for the treatment of hot flashes in breast cancer survivors, Psycho-Oncology, vol.21, issue.5, pp.487-492, 2007.
DOI : 10.1002/pon.1096

G. Elkins, Randomized Trial of a Hypnosis Intervention for Treatment of Hot Flashes Among Breast Cancer Survivors, Journal of Clinical Oncology, vol.26, issue.31, pp.5022-5026, 2008.
DOI : 10.1200/JCO.2008.16.6389

M. Lee, Acupuncture for treating hot flashes in breast cancer patients: a systematic review, Breast Cancer Research and Treatment, vol.53, issue.3, pp.497-503, 2009.
DOI : 10.1007/s10549-008-0230-z

S. Cho, Acupuncture for vasomotor menopausal symptoms, Menopause, vol.16, issue.5, pp.1065-1073, 2009.
DOI : 10.1097/gme.0b013e3181a48abd

G. Deng, A. Vickers, and Y. , Randomized, Controlled Trial of Acupuncture for the Treatment of Hot Flashes in Breast Cancer Patients, Journal of Clinical Oncology, vol.25, issue.35, pp.5584-90, 200110.
DOI : 10.1200/JCO.2007.12.0774

A. Daley, Exercice for vasomotor menopausal symptoms, Cochrane Data Base Sys Rev, vol.4, p.6108, 2007.

G. Rada, Non-hormonal interventions for hot flashes in women with a history of breast cancer, Cochrane Data Base Sys Rev, vol.9, p.4923, 2010.

R. Coombes, E. Hall, and L. Gibson, A Randomized Trial of Exemestane after Two to Three Years of Tamoxifen Therapy in Postmenopausal Women with Primary Breast Cancer, New England Journal of Medicine, vol.350, issue.11, pp.1081-92, 2004.
DOI : 10.1056/NEJMoa040331

J. Richardson, J. Smith, and G. Mccall, Hypnosis for nausea and vomiting in cancer chemotherapy: a systematic review of the research evidence, European Journal of Cancer Care, vol.88, issue.5, pp.402-414, 2007.
DOI : 10.1016/S0005-7894(82)80002-6

G. Gardani, R. Cerrone, and C. Biella, Effect of acupressure on nausea and vomiting induced by chemotherapy in cancer patients, Minerva Med, vol.97, pp.391-395, 2006.

A. Vickers, D. Straus, and B. Fearon, Acupuncture for Postchemotherapy Fatigue: A Phase II Study, Journal of Clinical Oncology, vol.22, issue.9, pp.1731-1735, 2004.
DOI : 10.1200/JCO.2004.04.102

D. Fellowes, K. Barnes, and S. Wilkinson, Aromatherapy and massage for symptoms relief in patients with cancer, Cochrane Data Base Sys Rev, vol.4, p.2287, 2008.

E. Ibrahim and A. Homaidh, Physical activity and survival after breast cancer diagnosis: meta-analysis of published studies, Medical Oncology, vol.100, issue.Suppl 2, pp.753-65, 2011.
DOI : 10.1007/s12032-010-9536-x

C. Palayer, Médecines non conventionnelles: legislation et pratiques professionnelles, Th D pharm, 2004.

L. Simon, D. Prebay, and A. Beretz, Médecines complémentaires et alternatives suivies par les patients cancéreux en France, Bull Cancer, vol.94, pp.483-491, 2007.

A. Lazarus, G. Delahaye, and L. Zelek, Les m??decines compl??mentaires et alternatives, Aider à vivre après un cancer, pp.283-291, 2010.
DOI : 10.1007/978-2-287-79501-5_22

D. Eisenberg, R. Davis, and S. Ettner, Perception about complementary therapies relative to conventionnal therapies among adults who use both: results from a national survey, Ann Intern Med, vol.15, pp.344-351, 2001.

M. Tascilar, D. Jonf, F. Verweij, and J. , Complementary and Alternative Medicine During Cancer Treatment: Beyond Innocence, The Oncologist, vol.11, issue.7, pp.732-773, 2006.
DOI : 10.1634/theoncologist.11-7-732

C. Velicer and C. Ulrich, Vitamin and Mineral Supplement Use Among US Adults After Cancer Diagnosis: A Systematic Review, Journal of Clinical Oncology, vol.26, issue.4, pp.665-73, 2008.
DOI : 10.1200/JCO.2007.13.5905

D. L. Dilhuydy, attrait pour les médecines complémentaires et alternatives en cancérologie : une réalité que les médecins ne peuvent ni ignorer, ni réfuter, Bull Cancer, vol.90, pp.623-631, 2003.
DOI : 10.1007/s10269-004-0055-2

M. Michael-phillips, D. Harding, C. Morton, and M. , Effects of soy-protein supplementation on epithelial proliferation in the histologically normal human breast, Am J Clin Nutr, vol.68, pp.1431-1467, 1998.

S. Quella, C. Lopriazi, and D. Barton, Evaluation of Soy Phytoestrogens for the Treatment of Hot Flashes in Breast Cancer Survivors: A North Central Cancer Treatment Group Trial, Journal of Clinical Oncology, vol.18, issue.5, pp.1068-74, 2000.
DOI : 10.1200/JCO.2000.18.5.1068

C. Duffy and M. Cyr, Phytoestrogens: Potential Benefits and Implications for Breast Cancer Survivors, Journal of Women's Health, vol.12, issue.7, pp.617-648, 2003.
DOI : 10.1089/154099903322404276

K. Fattinger and A. Meier-abt, Interactions entre la phytothérapie et les medicaments, Forum Med Suisse, pp.693-700, 2003.

L. Zelek, P. Latino-martel, and N. Pecollo, Vitamines et micronutriments, Aider à vivre après un cancer, pp.277-281, 2010.
DOI : 10.1007/978-2-287-79501-5_21

H. Norman, R. Butrum, and E. Feldman, The role of dietary supplements during cancer therapy, J Nutr, vol.133, pp.3794-3799, 2003.

C. Velicer and C. Ulrich, Vitamin and Mineral Supplement Use Among US Adults After Cancer Diagnosis: A Systematic Review, Journal of Clinical Oncology, vol.26, issue.4, pp.665-73, 2008.
DOI : 10.1200/JCO.2007.13.5905

S. Delanian, S. Balla-mekias, and J. Lefaix, Striking Regression of Chronic Radiotherapy Damage in a Clinical Trial of Combined Pentoxifylline and Tocopherol, Journal of Clinical Oncology, vol.17, issue.10, pp.3283-90, 1999.
DOI : 10.1200/JCO.1999.17.10.3283

T. Alpha, Beta carotene Cancer Prevention Study Group. The effect of vitamin E and beta carotene on the incidence of lung cancer and other cancers in male smokers, N Engl J Med, vol.330, pp.1029-1064, 1994.

B. Lawenda, K. Kelly, and E. Ladas, Should Supplemental Antioxidant Administration Be Avoided During Chemotherapy and Radiation Therapy?, JNCI Journal of the National Cancer Institute, vol.100, issue.11, pp.773-83, 2008.
DOI : 10.1093/jnci/djn148

URL : http://jnci.oxfordjournals.org/cgi/content/short/100/11/773

D. Cheuk, W. Yeung, and K. Chung, Acupuncture for insomnia, Cochrane Database Syst Rev, issue.3, p.5472, 2007.

Y. Sun, T. Gan, and J. Dubose, Acupuncture and related techniques for postoperative pain: a systematic review of randomized controlled trials, British Journal of Anaesthesia, vol.101, issue.2, pp.151-160, 2008.
DOI : 10.1093/bja/aen146

M. Karst, M. Winterhalter, and S. Münte, Auricular Acupuncture for Dental Anxiety: A Randomized Controlled Trial, Anesthesia & Analgesia, vol.104, issue.2, pp.295-300, 2007.
DOI : 10.1213/01.ane.0000242531.12722.fd

J. «. Klein, Que sais-je ?, p.126, 2001.

F. «. Chardon, Les sp??cificit??s de l'Art-th??rapie en oncologie m??dicale lors de l'accompagnement en fin de vie, Profession artthérapeute, pp.75-78, 2011.
DOI : 10.1016/B978-2-294-71144-2.50012-8